FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
-	Estimated average I	ourden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Asarpota Rajesh</u>				QĮ	2. Issuer Name <b>and</b> Ticker or Trading Symbol  QUESTCOR PHARMACEUTICALS INC  [ QCOR ]								heck all a	ship of Reportir applicable) rector ficer (give title	109	o Issuer o Owner er (specify	
(Last) (First) (Middle) 1300 NORTH KELLOGG DRIVE, SUITE D						3. Date of Earliest Transaction (Month/Day/Year) 02/24/2014								X Officer (give title Officer (specify below) Sr. VP., CFO and PAO			
(Street) ANAHEIM CA 92807 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								ne) X Fo	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da						Execution Date,		3. Transaction Disposed Of (D) (Instr. 3, 4) (5) (8)				d Sec Ber Ow	mount of urities eficially ned Following orted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect		
									Code	v	Amount (A) or (D)		A) or D)	Price	Trai	orted isaction(s) tr. 3 and 4)	
Common Stock <sup>(1)</sup> 02/24/2					/2014	2014		A		4,000(2)		A	A \$0.00		24,000	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security  3. Transaction Date Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amoun or Numbe of Title Shares		ount nber	8. Price of Derivative Security (Instr. 5)		Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)			

## Explanation of Responses:

- 1. Restricted stock award granted under the Questcor Pharmaceuticals, Inc. 2006 Equity Incentive Award Plan.
- 2. Represents a restricted stock award that vests subject to the achievement of certain performance-based criteria.

## Remarks:

/s/ Rajesh Asarpota

02/26/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.